Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | EVP R&D, Chief Medical Officer | September 01, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date September 01, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 65,389 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 5,000 · Balance 74,389 F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Row 2 · 2026-09-01 · Sale · Disposed 9,000 · Balance 65,389 F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.59 · Expires 2032-02-18 | Direct | 61,276 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Disposed 5,000 · Balance 61,276 F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4: These options are fully vested in accordance with their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
F4: These options are fully vested in accordance with their terms.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBIREO PHARMA, INC.
Report date March 02, 2023 · Filed March 02, 2023
Section 16 reporting ended · disclosed 2023-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-02 · Disposition to issuer · Disposed 10,495 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share"). F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F5: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share").
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time").
F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027;
F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect.
F5: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2023 Filed Feb 22, 2023 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 10,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006511 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 8,722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006511 · form4.xml · derivative · entry 9 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,167 Underlying: Ordinary Shares · 8,722 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 2,656 | $28.07 | $74,553.92 |
DisclosureSEC source: 0001127602-23-006511 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,060 Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 8,722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006511 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 16:10 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantCommon Stock | 10,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-059652 · doc4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,495 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs will vest in equal annual installments over three years from December 1, 2022 (but, in any case, to be fully vested on the day prior to the annual meeting for the third fiscal year that begins following the date of grant), subject to the director's continued service on the issuer's board of directors on the applicable vesting dates. F2 · balance_after: Represents 10,495 restricted stock units. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 22:34 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 11,983 | $24.76 | $296,649.95 |
DisclosureSEC source: 0001127602-22-006622 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,994 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 of Table I is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.58 to $25.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 12,037 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · derivative · entry 12 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,114 Underlying: Ordinary Shares · 12,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/22/2022. F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/22/2022. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,539 | $25.01 | $88,510.39 |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · nonDerivative · entry 7 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,977 Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 12,037 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · nonDerivative · entry 6 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,875 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · derivative · entry 11 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,875 Underlying: Ordinary Shares · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020. F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 2,022 | $25.08 | $50,711.76 |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · nonDerivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,479 Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · nonDerivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. Read SEC document |
| February 20, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 10,096 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · derivative · entry 10 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,191 Underlying: Ordinary Shares · 10,096 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/20/2021. F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/20/2021. Read SEC document |
| February 20, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 2,966 | $25.08 | $74,387.28 |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,626 Read SEC document |
| February 20, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 10,096 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 34,889 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · derivative · entry 9 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,889 Underlying: Ordinary Shares · 34,889 shares Expires not disclosed F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/18/2023. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/18/2023. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 139,554 | $0.00 Strike: $25.08 | $0.00 |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · derivative · entry 8 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,554 Underlying: Ordinary Shares · 139,554 shares Expires 2032-02-18 F3 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:40 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 2,306 | $25.17 | $58,042.02 |
DisclosureSEC source: 0001127602-22-006332 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,496 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:24 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,375 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-22-005455 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:24 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,069 | $26.79 | $28,638.51 |
DisclosureSEC source: 0001127602-22-005455 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,802 Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:24 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005455 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 20:25 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 5,647 | $30.60 | $172,798.20 |
DisclosureSEC source: 0001127602-21-025401 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,496 Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 20:25 UTC | Alkermes plc. ALKS · Entity 2392 | GrantOrdinary Shares | 15,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-025401 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,143 F1 · price: These ordinary shares were acquired by the reporting person as a result of the partial vesting of performance-vesting restricted stock unit awards ("PRSUs") granted to the reporting person on February 20, 2020. The vesting of this portion of the PRSUs was triggered by the achievement of certain pre-specified pipeline performance goals. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:36 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 882 | $24.60 | $21,697.20 |
DisclosureSEC source: 0001127602-21-019721 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 22:51 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 1,250 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-21-019458 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 22:51 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 368 | $23.50 | $8,648.00 |
DisclosureSEC source: 0001127602-21-019458 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882 Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 22:51 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-019458 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 20:35 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 28,920 | $19.72 | $570,287.94 |
DisclosureSEC source: 0001127602-21-013891 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 of Table I is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.32 to $19.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:54 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 48,151 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-007793 · form4.xml · derivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,151 Underlying: Ordinary Shares · 48,151 shares Expires not disclosed F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/22/2022. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/22/2022. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:54 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 196,484 | $0.00 Strike: $19.73 | $0.00 |
DisclosureSEC source: 0001127602-21-007793 · form4.xml · derivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,484 Underlying: Ordinary Shares · 196,484 shares Expires 2031-02-22 F1 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022. Read SEC document |
| February 21, 2021 Filed Feb 24, 2021 02:25 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-007458 · form4.xml · derivative · entry 6 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Ordinary Shares · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/21/2020. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/21/2020. Read SEC document |
| February 21, 2021 Filed Feb 24, 2021 02:25 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 2,022 | $19.58 | $39,590.76 |
DisclosureSEC source: 0001127602-21-007458 · form4.xml · nonDerivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,920 Read SEC document |
| February 21, 2021 Filed Feb 24, 2021 02:25 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-007458 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2021 Filed Feb 24, 2021 02:25 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 10,095 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-007458 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,287 Underlying: Ordinary Shares · 10,095 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. Read SEC document |
| February 20, 2021 Filed Feb 24, 2021 02:25 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,064 | $19.58 | $59,993.12 |
DisclosureSEC source: 0001127602-21-007458 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,067 Read SEC document |
| February 20, 2021 Filed Feb 24, 2021 02:25 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 10,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-007458 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:25 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006563 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,375 Underlying: Ordinary Shares · 3,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/16/2019. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/16/2019. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:25 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,172 | $19.79 | $23,193.88 |
DisclosureSEC source: 0001127602-21-006563 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,036 Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:25 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006563 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2020 Filed Jun 8, 2020 20:21 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 1,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019127 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Ordinary Shares · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 6/7/18. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 6/7/18. Read SEC document |
| June 07, 2020 Filed Jun 8, 2020 20:21 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 368 | $17.19 | $6,325.92 |
DisclosureSEC source: 0001127602-20-019127 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,833 Read SEC document |
| June 07, 2020 Filed Jun 8, 2020 20:21 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019127 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:13 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,875 | $0.00 Strike: $32.57 | $0.00 |
DisclosureSEC source: 0001127602-20-007184 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,825 Underlying: Ordinary Shares · 6,875 shares Expires 2029-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/21/2020. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:13 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 2,004 | $20.24 | $40,560.96 |
DisclosureSEC source: 0001127602-20-007184 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,951 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:13 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-007184 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2020 Filed Jan 15, 2021 21:37 UTC Amendment | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-001769 · form4a.xml · derivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 Underlying: Ordinary Shares · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Table II of the Form 4 filed on February 24, 2020 inadvertently reported an exercise by the reporting person of an employee stock option in lieu of reporting the vesting of a restricted stock unit award.??This amendment is being filed to correct Table II to show the vesting of such restricted stock unit award.??All other information reported in the original Form 4 remains the same. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/21/2020. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/21/2020. Read SEC document |
| February 21, 2020 Filed Jan 15, 2021 21:37 UTC Amendment | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-001769 · form4a.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:13 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 40,382 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-007184 · form4.xml · derivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,382 Underlying: Ordinary Shares · 40,382 shares Expires not disclosed F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/20/2021. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/20/2021. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:13 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 168,856 | $0.00 Strike: $20.43 | $0.00 |
DisclosureSEC source: 0001127602-20-007184 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,856 Underlying: Ordinary Shares · 168,856 shares Expires 2030-02-20 F1 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/20/2021. Read SEC document |
| February 16, 2020 Filed Feb 18, 2020 21:10 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006020 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Ordinary Shares · 3,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.